Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Astellas Pharma Inc., a leading player in the pharmaceutical preparation manufacturing industry, is headquartered in Tokyo, Japan. Founded in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, Astellas has established a strong presence in key global markets, including North America, Europe, and Asia.
The company focuses on innovative solutions in areas such as urology, oncology, and immunology, with a commitment to addressing unmet medical needs. Astellas is renowned for its unique products, including the prostate cancer treatment Xtandi, which has significantly impacted patient outcomes.
With a robust pipeline and a dedication to research and development, Astellas continues to solidify its market position, earning recognition for its contributions to healthcare and patient well-being.
+18 vs industry average
Astellas’s score of 60 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing has above-average carbon intensity
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Astellas, a Pharmaceutical Preparation Manufacturing company based in Japan, reported total Scope 1, 2, and 3 carbon emissions of approximately 1.386 billion kg CO2e in 2024. This includes about 52.2 million kg CO2e from Scope 1, 55.6 million kg CO2e from Scope 2, and 1.276 billion kg CO2e from Scope 3.
In 2023, Astellas's total emissions were approximately 1.284 billion kg CO2e, comprising about 59.2 million kg CO2e from Scope 1, 63.0 million kg CO2e from Scope 2, and 1.121 billion kg CO2e from Scope 3. For 2022, total emissions were approximately 1.014 billion kg CO2e, with Scope 1 at about 61.2 million kg CO2e, Scope 2 at about 56.5 million kg CO2e, and Scope 3 at about 893.6 million kg CO2e.
Astellas has set several climate commitments. The company aims to achieve Net Zero GHG emissions by 2050. Near-term targets, validated by the Science Based Targets initiative (SBTi), include reducing absolute Scope 1 and 2 GHG emissions by 63% by fiscal year 2030 from a fiscal year 2015 base year. Additionally, Astellas commits to reducing absolute Scope 3 GHG emissions by 37.5% by fiscal year 2030 from a fiscal year 2015 base year. These targets are consistent with keeping global warming to 1.5°C.
2030
63% reduction in Scope 2
Astellas Pharma Inc. commits to reduce absolute scope 1 and 2 GHG emissions 63% by FY2030 from a FY2015 base year.
2030
63% reduction in Scope 1
Astellas Pharma Inc. commits to reduce absolute scope 1 and 2 GHG emissions 63% by FY2030 from a FY2015 base year.
2030
37.5% reduction in scope 3 total
Astellas Pharma Inc. commits to reduce absolute scope 3 GHG emissions 37.5% by FY2030 from a FY2015 base year.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Astellas’s sustainability data and climate commitments
Data year: 2024
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more